Onychomycosis Market By Types (Distal Subligual, White superficial, Proximal Subligual, Candida and Others), By Treatment (Drug treatment, Topical therapy and others), By Distribution channel (Hospital pharmacies, Retail pharmacies and others) and Geography


Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Global onychomycosis market is expected to grow at a CAGR of 7.7% over the 2021-2027 forecast periods reaching a value of US$ 6,068.44 by the end of 2027. Onychomycosis constitutes 20% to 40% of all globe-wide onycho-pathies. An article published on ScienceDirect reported that the prevalence of onychomycosis around the world currently ranges from 2% to 50%, representing approximately 30% of superficial mycotic infections and 50% of all nail disorders. In addition, onychomycosis affects predominantly adults aged between 30 and 60. Lack of awareness about onychomycosis, sudden outbreak of the Covid-19 pandemic caused a great deal of chaos leading to an economic crisis. This has contributed to decrease the market growth rates. Moreover, emerging economies like China, India, and others will generate new prospects for the global market for onychomycosis. Tinea unguium, or onychomycosis, is a fungal infection of the fingernails or toenails that can affect any part of the nail unit, including the matrix, bed, or plate. This can result in pain, deformity, and discomfort, as well as significant difficulties and a reduction in quality of life. Subungual onychomycosis, distal and lateral subungual onychomycosis, proximal subungual onychomycosis, endonyx onychomycosis, and complete dystrophic onychomycosis are all kinds of onychomycosis. Only around half of nail dystrophies are caused by fungus, hence onychomycosis accounts for one-third of fungal skin infections. The onychomycosis treatment market is being driven by the growing elderly population, rising prevalence of onychomycosis, and diabetes population worldwide, as well as growing knowledge about the potential hazards of onychomycosis.

Onychomycosis Market Summary

Study Period


Base Year




Largest Market

North America

Fastest Growing Market

Asia Pacific

Non-profit organizations plan educational events to spread information among people about treating onychomycosis. For example, the British Association of Dermatologists has distributed leaflets among patients which provide full onychomycosis treatment guidance. Similar awareness programmes are expected to increase awareness among patients in both developed and developing economies, driving onychomycosis therapy market growth over the forecast period.

Key Features of the Reports

  • In March 2020, Kaken Pharmaceuticals Co., Ltd. announced the launch of Jublia in Hong Kong.
  • In February 2019, Moberg Pharma AB signed a license agreement with Bayer AG under which Bayer AG will be responsible for the marketing, selling and distribution of MOB-015 in Europe.
  • In July 2018, Eisai Co., Ltd., and Sato Pharmaceuticals Co., Ltd. announced the launch of NAILIN in Japan.

Onychomycosis Market Segmentation

By Types
  • Distal Subligual
  • White superficial
  • Proximal Subligual
  • Candida
  • Others
By Treatment
  • Drug treatment
  • Topical therapy
  • others
Distribution Channel
  • Hospital pharmacies
  • Retail pharmacies
  • others
By Geography
North America
  • US
  • Canada
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Spain
  • Rest of Europe
  • China
  • Japan
  • India
  • Korea
  • Australia & New Zealand
  • Rest of APAC
South America
  • Brazil
  • Argentina
  • Columbia
  • Mexico
  • Rest of South America
Middle East and Africa
  • UAE
  • Egypt
  • Nigeria
  • South Africa
  • Rest of MEA

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

  • Bausch Healthcare companies
  • Galderma S.A.
  • Celtic Pharma
  • Anacor Pharmaceuticals Inc.
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • GlaxoSmithKline
  • Bayer AG
  • Reddy’s Laboratories Ltd